For the quarter ended December 2024, Idexx Laboratories (IDXX) reported revenue of $954.29 million, up 5.8% over the same period last year. EPS came in at $2.62, compared to $2.32 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $936.78 million, representing a surprise of +1.87%. The company delivered an EPS surprise of +9.17%, with the consensus EPS estimate being $2.40.While investors scrutinize revenue and earnings changes year-over-year and how they compare with W ...

Core Insights - Idexx Laboratories exceeded earnings expectations for Q4 2024, driven by strong performance in its Companion Animal Group segment [2][3] Financial Performance - Q4 2024 revenue reached $954 million, surpassing the expected $935 million, while EPS was $2.62, exceeding the forecasted $2.40 [2][4] - Year-over-year revenue growth was 5.8%, up from $901.6 million in Q4 2023, and EPS increased by 13% from $2.32 [4] - Gross margin improved to 59.8% from 58.4% year-over-year, and operating margin slightly increased to 27.4% from 27.2% [4][9] Business Overview - Idexx Laboratories specializes in veterinary diagnostics, with its Companion Animal Group being the primary revenue driver [5] - The company offers a range of diagnostic tests, laboratory services, and practice management platforms [5] Recent Developments - The introduction of the inVue Dx™ Cellular Analyzer aims to enhance veterinary workflows and diagnostic efficiencies [6][9] - The Companion Animal Group diagnostics segment reported a 6% growth, while VetLab consumables sales increased by 12%, indicating a strong recurring revenue model [7] - The Water segment also saw an 8% year-over-year growth, supported by effective pricing strategies and increased international demand [8] Strategic Focus and Future Outlook - Management projects 2025 revenue between $4.06 billion and $4.17 billion, with EPS guidance of $11.74 to $12.24, driven by growth in the CAG segment and international market expansion [11] - The company plans to execute share repurchases of approximately $1.5 billion, reflecting confidence in future cash flow [12] - Idexx is focusing on high-growth areas such as oncology diagnostics and emerging markets [13]

Financial Performance - Idexx Laboratories reported quarterly earnings of $2.62 per share, exceeding the Zacks Consensus Estimate of $2.40 per share, and up from $2.32 per share a year ago, representing an earnings surprise of 9.17% [1] - The company posted revenues of $954.29 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.87%, compared to year-ago revenues of $901.6 million [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $3.02 on revenues of $1.02 billion, and for the current fiscal year, it is $11.95 on revenues of $4.16 billion [7] - The estimate revisions trend for Idexx is currently unfavorable, leading to a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Instruments industry, to which Idexx belongs, is currently in the top 34% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8] - Teleflex, another company in the same industry, is expected to report quarterly earnings of $3.86 per share, reflecting a year-over-year change of +14.2% [9]

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces Fourth Quarter and Full Year 2024 Results WESTBROOK, Maine, February 3, 2025 — IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced fourth quarter and full year results. "IDEXX had a solid finish to 2024, supported by continued high levels of execution by IDEXX teams globally," said Jay Mazelsky, President and Chief Executive Officer. "The ...

IDEXX Laboratories, Inc. (IDXX) is set to release fourth-quarter 2024 results on Feb. 3, before the opening bell.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.80, which surpassed the Zacks Consensus Estimate by 4.1%. IDEXX Laboratories’ earnings beat estimates in three of the trailing four quarters and missed in one, the average surprise being 0.85%.IDXX’s Q4 EstimatesThe Zacks Consensus Estimat ...

IDEXX Laboratories, Inc. (IDXX) has unveiled the IDEXX Cancer Dx, a first-of-its-kind diagnostic panel with early detection of lymphoma in dogs. This affordable and accessible blood test can be added to panels for sick pets and integrated into annual wellness screenings for as low as $15, providing veterinarians in the United States with actionable results within two to three days.The test is especially crucial for the 20 million dogs in North America who face an increased risk of cancer. Early detection an ...

Core Insights - IDEXX Laboratories, Inc. has launched IDEXX Cancer Dx™, a pioneering diagnostic panel for early detection of lymphoma in dogs, particularly targeting the 20 million dogs at higher risk for cancer in North America [1][2][3] - The test is affordable, costing as low as $15, and provides actionable results within 2–3 days, making it accessible for veterinarians [1][4] - Cancer is a leading cause of death in dogs, with 1 in 4 dogs in the U.S. expected to be diagnosed with cancer in their lifetime, highlighting the critical need for early detection [2][3] Company Overview - IDEXX is recognized as a global leader in pet healthcare innovation, with over 40 years of experience in veterinary research and technology development [3][6] - The company employs approximately 11,000 people and offers solutions in more than 175 countries, indicating a strong global presence [7] - IDEXX Cancer Dx is designed to integrate seamlessly into existing veterinary workflows, enhancing the ability of veterinarians to manage cancer proactively [6][4] Market Demand - A recent survey revealed that 73% of pet owners are interested in cancer screening tests for their pets, indicating a strong market demand for proactive healthcare solutions [2][4] - The IDEXX Cancer Dx panel aims to improve the quality of life for canine cancer patients by enabling earlier clinical diagnoses compared to traditional methods [4][5] Future Plans - IDEXX plans to expand the Cancer Dx panel over the next three years to cover a broader range of canine cancer cases, further transforming cancer detection and intervention [1][3] - The IDEXX Cancer Dx test for canine lymphoma will be available at IDEXX Reference Laboratories in the U.S. and Canada starting in late March 2025 [5][9]

IDEXX’s (IDXX) business continues to be dampened by currency impacts and uncertain macroeconomic conditions. The stock carries a Zacks Rank #4 (Sell) currently.Concerning Factors for IDXXIn recent times, U.S. clinical visit growth levels have been constrained by persistent staffing challenges at veterinary clinics and the cumulative impacts of broader macroeconomic challenges on consumers. Meanwhile, challenges in the Asia-Pacific, including the impacts of reduced swine testing in China and lower health scr ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores. What ...

BOSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Sustainability Roundtable, Inc. (SR Inc), a leader in strategic advisory and support services, proudly announces the recipients of its 2024 Sustainable Business & Enterprise Roundtable (SBER) Awards. Presented the eve before its Summit for Sustainable Business VIII: Decarbonizing Corporate Global Operations at the St. Regis hotel in Washington, D.C., these recognitions commemorate SBER's 2024 standout sustainability leaders. Award Recipients and Achievements SR Inc ...